HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Psychiatry
Meta-analysis
Systematic review of stigma in adult ADHD and quality of life outcomes
Internalized stigma hurts quality of life for adults with ADHD
This systematic review synthesizes findings from 17 papers regarding stigma in adults with attention deficit hyperactivity disorder. The aut…
Adults with ADHD who feel deep shame about their condition report worse physical health, lower self-esteem, and poorer social connections.
Frontiers
Apr 29, 2026
Psychiatry
FDA Approval
FDA Approves Mydayis (mixed salts of a single-entity amphetamine) for ADHD in Patients 13 and Older
FDA approves new ADHD drug Mydayis for patients 13 and older.
FDA approved Mydayis, a CNS stimulant, for ADHD in patients 13 years and older. The drug is taken once daily upon awakening and may last up …
The FDA approved Mydayis, a once-daily stimulant for ADHD in people 13 and older. It can last up to 16 hours, which may cause insomnia. This…
FDA
Apr 29, 2026
Psychiatry
Cohort
ADHD and ASD polygenic risk scores correlate with antipsychotic responsiveness in schizophrenia postmortem brains
Genes for ADHD and Autism May Predict Schizophrenia Drug Response
This postmortem brain study in 24 patients with schizophrenia and 48 controls examined polygenic risk scores for ADHD and ASD. It found a su…
Genes tied to ADHD and autism may predict how well antipsychotic drugs work in schizophrenia patients.
Frontiers
Apr 27, 2026
Psychiatry
Cohort
MDD polygenic scores show adolescence-specific effects on child depressive symptoms in Norwegian cohort
Teen Depression Linked to Genes That "Switch On" at Puberty
This cohort study of children from the Norwegian Mother, Father and Child Cohort assessed depressive symptoms at ages 8 and 14. Children's o…
Your teen's depression risk may be written in their genes, but only becomes visible during puberty's hormonal storm.
medRxiv
Apr 26, 2026
Psychiatry
Case-Control
Adults with ADHD show higher emotional eating and lower cognitive flexibility in case-control study
Adults with ADHD show more emotional eating and less mental flexibility in study
A case-control study of 76 adults with ADHD and 69 healthy controls found the ADHD group had significantly higher emotional eating scores (t…
Adults with ADHD eat more when stressed and struggle to shift their thinking compared to those without the condition, according to new findi…
Frontiers
Apr 7, 2026
Psychiatry
Speech features differ in children with ADHD and show medication-associated changes in small study
Could a child's voice reveal ADHD and track medication effects?
A longitudinal case-control study of 27 children with ADHD and 27 controls found baseline differences in vocal features and medication-assoc…
A child's voice reveals ADHD traits like lower pitch and unstable rhythm, with medication helping stabilize speech patterns in a new study.
medRxiv
Apr 3, 2026
Pediatrics
RCT
Cognitive training programs ARAM and PETRA show improvements in ADHD symptoms and executive functions in preschoolers
Two cognitive training programs show promise for preschoolers with ADHD in small study
A randomized controlled trial in 47 preschool children with ADHD found that both ARAM and PETRA cognitive training programs improved inhibit…
Two cognitive training programs improved attention and behavior in preschoolers with ADHD, with one showing slightly larger daily life benef…
Apr 3, 2026
Pediatrics
RCT
Methylphenidate plus iron shows earlier response in children with severe ADHD and iron deficiency
Iron supplements with ADHD medication may help children with both conditions
A small RCT of 50 children with severe ADHD and iron deficiency in Bangladesh compared methylphenidate plus iron to methylphenidate alone ov…
Adding iron supplements to ADHD medication helped children with both conditions improve symptoms faster than medication alone.
Apr 3, 2026
Psychiatry
FDA Approval
FDA Approves Methylphenidate Hydrochloride Extended-Release Tablets for ADHD and Narcolepsy
The FDA has approved a new, longer-acting generic version of a common ADHD and narcolepsy medication.
The FDA has approved methylphenidate hydrochloride extended-release tablets for the treatment of Attention Deficit Hyperactivity Disorder (A…
The FDA approved a new generic ADHD and narcolepsy medicine that works for about 8 hours, offering a longer-lasting option for patients 6 ye…
FDA
Mar 31, 2026